{"filing":{"accession_number":"0001411690-26-000043","cik":"0001411690","ticker":"BNGO","company_name":"Bionano Genomics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"bngo-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169026000043/bngo-20260810.htm"},"events":[{"id":26520,"run_id":24106,"accession_number":"0001411690-26-000043","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Bionano's Q2 2026 financial results for the period ended June 30, 2026. The press release reports total revenue of $8.2 million (21% YoY increase), consumables revenue of $4.3 million (31% increase), gross margin of 53%, and provides forward guidance for Q3 and full-year 2026. The filing is properly classified under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the standard format for earnings disclosures.","company_name":"Bionano Genomics, Inc.","ticker":"BNGO","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27674,"accession_number":"0001411690-26-000043","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Bionano's Q2 2026 financial results for the period ended June 30, 2026. The press release reports total revenue of $8.2 million (21% YoY increase), consumables revenue of $4.3 million (31% increase), gross margin of 53%, and provides forward guidance for Q3 and full-year 2026. The filing is properly classified under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:07:38.079541+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27674,"accession_number":"0001411690-26-000043","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Bionano's Q2 2026 financial results for the period ended June 30, 2026. The press release reports total revenue of $8.2 million (21% YoY increase), consumables revenue of $4.3 million (31% increase), gross margin of 53%, and provides forward guidance for Q3 and full-year 2026. The filing is properly classified under Item 2.02 (Results of Operations and Financial Condition) with the full press release attached as Exhibit 99.1, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:07:38.079541+00:00","company_name":"Bionano Genomics, Inc.","ticker":"BNGO","filing_date":"2026-08-10"}]}